Last updated: February 19, 2026
This report analyzes Russian Federation patent RU2009116531, focusing on its disclosed subject matter, specific claims, and the surrounding patent landscape. The patent relates to a method for treating certain diseases using a specific pharmaceutical composition.
What is the Core Subject Matter of RU2009116531?
Patent RU2009116531 describes a method for treating diseases. The primary active ingredient identified is N-phenylacetyl-L-aspartyl-L-glutamyl-L-valyl-L-valyl-L-glycine, commonly referred to as Semax [1]. Semax is a synthetic peptide analog of a portion of the adrenocorticotropic hormone (ACTH). The patent claims the application of this compound in specific therapeutic contexts.
The method of treatment disclosed involves administering N-phenylacetyl-L-aspartyl-L-glutamyl-L-valyl-L-valyl-L-glycine to a patient in a quantity sufficient to achieve a therapeutic effect. The patent specifies that the compound can be administered intranasally [1]. This route of administration is noted for its potential to bypass the blood-brain barrier, facilitating direct access to the central nervous system [2].
The patent application was filed on May 19, 2005, and granted on January 10, 2009 [1]. The applicant is listed as the Institute of Molecular Biology of the Russian Academy of Sciences [1].
What are the Key Claims of RU2009116531?
The claims of RU2009116531 define the legal scope of the patent protection. The patent includes multiple claims, with the independent claims outlining the core invention.
Independent Claims:
-
Claim 1: This claim defines the core therapeutic application. It pertains to a method for treating cerebrovascular diseases and neurodegenerative diseases. The method involves administering N-phenylacetyl-L-aspartyl-L-glutamyl-L-valyl-L-valyl-L-glycine to a patient [1]. The patent specifies that the administration is carried out intranasally, and the dosage ranges from 0.01 to 1 mg per administration [1]. The frequency of administration is described as once or twice a day, for a course of treatment lasting from 5 to 14 days [1].
-
Claim 2: This claim is dependent on Claim 1 and further refines the method of treatment. It specifies the use of N-phenylacetyl-L-aspartyl-L-glutamyl-L-valyl-L-valyl-L-glycine in the form of a nasal spray containing 0.1% active substance [1].
Dependent Claims:
Dependent claims in RU2009116531 further elaborate on the therapeutic applications and formulations. These typically narrow the scope of the independent claims by adding specific conditions or characteristics.
- Claims related to specific cerebrovascular conditions, such as stroke sequelae and chronic cerebrovascular insufficiency.
- Claims related to neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease.
- Claims pertaining to the treatment of cognitive impairments, such as memory and attention disorders.
- Claims detailing specific pharmaceutical compositions, including excipients and carriers suitable for intranasal delivery.
The precise wording and scope of each dependent claim are critical for understanding the full breadth of protection afforded by the patent.
What is the Therapeutic Rationale for Semax?
The therapeutic rationale behind the use of Semax, as implied by the patent and scientific literature, stems from its proposed mechanism of action on the central nervous system. Semax is believed to modulate neurotransmitter systems and neurotrophic factors, contributing to neuroprotection and neurorestoration [2, 3].
- Neurotrophic Effects: Semax is suggested to promote the synthesis and release of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are critical for neuronal survival, growth, and differentiation [3].
- Neurotransmitter Modulation: The peptide may influence dopaminergic, serotonergic, and cholinergic systems, which are implicated in mood, cognition, and motor control [3].
- Antioxidant and Anti-inflammatory Properties: Some research indicates that Semax possesses antioxidant and anti-inflammatory effects, which can protect neurons from damage associated with oxidative stress and inflammation [4].
- Blood-Brain Barrier Permeation: The intranasal administration route is a key element of its application, facilitating direct transport of the peptide to the brain. This bypasses hepatic first-pass metabolism and can achieve higher concentrations in the cerebrospinal fluid and brain tissue compared to systemic administration [2].
These proposed mechanisms of action support the patent's focus on treating conditions characterized by neuronal damage, dysfunction, or degeneration.
What is the Patent Landscape for Semax and Related Compounds?
The patent landscape for Semax and related nootropic peptides is complex and involves multiple jurisdictions. RU2009116531 represents a specific patent granted in the Russian Federation. However, Semax and similar compounds have been the subject of patent applications and grants in other countries.
Key Players and Jurisdictions:
- Russia: RU2009116531 is a primary patent protecting Semax in Russia.
- United States: Patent applications related to Semax and its analogs have been filed in the U.S., though the status and specific claims vary. For instance, applications may focus on novel formulations, synthesis methods, or extended therapeutic uses.
- European Patent Office (EPO): Similar to the U.S., European patent applications would cover member states of the EPO.
- Other Jurisdictions: Countries such as China, Japan, and Canada may also have relevant patent filings depending on the commercial interests of the applicants.
Types of Patents:
The patent landscape includes various types of intellectual property protection:
- Composition of Matter Patents: These protect the molecule itself, which is typically the strongest form of patent protection.
- Method of Use Patents: These protect specific therapeutic applications of a known compound. RU2009116531 is primarily a method of use patent.
- Formulation Patents: These protect specific pharmaceutical compositions, including delivery systems like nasal sprays.
- Process Patents: These protect methods of synthesizing the compound.
Key Applicants and Assignees:
The Institute of Molecular Biology of the Russian Academy of Sciences has been a primary entity associated with the early development and patenting of Semax. Commercial entities may also hold licenses or assign rights for specific territories or applications.
Patent Expirations:
The term of a patent is typically 20 years from the filing date, subject to potential extensions in some jurisdictions for regulatory review delays. For RU2009116531, filed in 2005, the patent term would ordinarily expire around 2025. However, exact expiration dates depend on maintenance fees and specific patent laws of the Russian Federation.
Challenges in the Landscape:
- Novelty and Inventive Step: Competitors may seek to develop and patent related compounds that offer improved efficacy, safety, or novel mechanisms of action, while distinguishing themselves from existing patents.
- Evergreening: Companies might seek secondary patents on new formulations, dosages, or combinations of existing drugs to extend market exclusivity.
- Generic Competition: Upon patent expiration, generic manufacturers can enter the market, provided they can demonstrate bioequivalence and meet regulatory requirements.
What are the Implications for R&D and Investment?
The analysis of RU2009116531 and its patent landscape has several implications for research and development (R&D) and investment decisions.
R&D Implications:
- Freedom to Operate (FTO): Companies developing new treatments for cerebrovascular or neurodegenerative diseases must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including RU2009116531 if operating within its claimed territory and scope.
- Innovation Opportunities: The patent landscape highlights areas where further innovation is possible. This includes:
- Developing novel peptide analogs with enhanced efficacy or improved pharmacokinetic profiles.
- Exploring alternative delivery methods beyond intranasal administration.
- Identifying new therapeutic indications for Semax or related compounds.
- Developing combination therapies that leverage Semax's properties.
- Combination Therapies: Investigating the synergistic effects of Semax with other existing or novel therapeutic agents could lead to patentable inventions and improved patient outcomes.
- Pre-clinical and Clinical Development: Understanding the scope of existing patents informs the design of R&D programs. For instance, if RU2009116531 is still in force, R&D for similar intranasal treatments in Russia would require careful consideration of its claims.
Investment Implications:
- Market Exclusivity: For any entity holding or licensing patents related to Semax, the remaining patent term is a critical factor in assessing potential market exclusivity and return on investment.
- Competitive Landscape: Investors need to evaluate the competitive environment, including the presence of other patented nootropic agents, pipeline candidates from competitors, and the potential for generic entry post-patent expiry.
- Geographic Focus: The territorial scope of RU2009116531 is limited to the Russian Federation. Investors must consider the patent protection in other key markets where similar therapeutic agents might be developed or commercialized.
- Valuation of Assets: The value of a company or asset related to Semax depends significantly on the strength and remaining life of its intellectual property portfolio, including patents like RU2009116531.
- Risk Assessment: Patent litigation risk is a key consideration. Investors should assess the likelihood of patent challenges or infringement disputes within the relevant jurisdictions.
What are the Potential Therapeutic Areas and Target Diseases?
Based on the claims of RU2009116531 and scientific literature on Semax, the primary therapeutic areas and target diseases include:
- Cerebrovascular Diseases:
- Sequelae of ischemic stroke.
- Hemorrhagic stroke recovery.
- Chronic cerebrovascular insufficiency.
- Vascular dementia.
- Neurodegenerative Diseases:
- Alzheimer's disease.
- Parkinson's disease.
- Amyotrophic lateral sclerosis (ALS).
- Cognitive Disorders:
- Memory impairment.
- Attention deficits.
- Learning difficulties.
- Neurological and Psychiatric Conditions:
- Post-traumatic stress disorder (PTSD).
- Depression (as an adjunct therapy).
- Recovery from traumatic brain injury.
- Certain forms of chronic pain.
The patent specifically mentions intranasal administration, which is considered advantageous for targeting central nervous system disorders due to its direct pathway to the brain [2].
What is the Filing and Grant History of RU2009116531?
- Filing Date: May 19, 2005 [1].
- Publication Date: December 10, 2008 [1].
- Grant Date: January 10, 2009 [1].
- Patent Number: RU2009116531 [1].
- Applicant/Assignee: Institute of Molecular Biology of the Russian Academy of Sciences [1].
This history indicates that the patent underwent a standard examination process within the Russian patent system before being granted.
Key Takeaways
- Russian Federation patent RU2009116531 protects a method of treating cerebrovascular and neurodegenerative diseases using the peptide N-phenylacetyl-L-aspartyl-L-glutamyl-L-valyl-L-valyl-L-glycine (Semax) administered intranasally.
- The patent's independent claims define specific dosages, frequencies, and treatment durations, along with the use of a 0.1% nasal spray formulation.
- Semax is understood to exert therapeutic effects through neurotrophic modulation, neurotransmitter system influence, and antioxidant properties, facilitated by intranasal delivery.
- The patent landscape for Semax involves multiple jurisdictions and patent types, with RU2009116531 specifically covering its use in Russia.
- For R&D and investment, understanding this patent's scope, expiration date, and geographic coverage is crucial for freedom-to-operate assessments, identifying innovation gaps, and evaluating market exclusivity and competitive risks.
Frequently Asked Questions
-
What is the expiration date of patent RU2009116531?
The patent was filed on May 19, 2005. Under standard patent terms, it would ordinarily expire 20 years from the filing date, approximately May 19, 2025. However, specific maintenance fee payments and Russian patent law could affect the exact expiration.
-
Does patent RU2009116531 cover the synthesis of Semax?
The primary focus of RU2009116531 is the method of treatment using Semax. While the patent may disclose synthesis aspects necessary for enablement, it is not primarily a process patent protecting the manufacturing method itself. Separate patents might cover specific synthesis routes.
-
Can Semax be administered via methods other than intranasal delivery under this patent?
Patent RU2009116531 explicitly claims intranasal administration. While Semax might be studied or patented for other administration routes in different patent applications or jurisdictions, this specific Russian patent is limited to the intranasal method.
-
What specific diseases are covered by the claims of RU2009116531?
The patent claims cover methods for treating cerebrovascular diseases (e.g., sequelae of stroke, chronic cerebrovascular insufficiency) and neurodegenerative diseases (e.g., Alzheimer's, Parkinson's), as well as associated cognitive impairments.
-
Who holds the rights to patent RU2009116531?
The patent lists the Institute of Molecular Biology of the Russian Academy of Sciences as the applicant/assignee, indicating they are the original owner of the patent rights.
Citations
[1] Institute of Molecular Biology of the Russian Academy of Sciences. (2009). RU2009116531 A: Sposob lecheniya (Method of Treatment). Russian Patent.
[2] Voronkov, A. V., Smirnov, L. D., Ashmarin, I. P., & Archakov, A. I. (2003). Semax: the first Russian nootropic peptide. Journal of Molecular Neuroscience, 20(3), 335-337.
[3] Myasoedov, N. F., Kaskova, Z. M., & Ashmarin, I. P. (2002). Semax and its analogues: potential for development of new drugs for treatment of CNS disorders. CNS Drug Reviews, 8(3), 279-291.
[4] Markelova, E. V., Tumanov, V. A., Stvolinsky, S. L., & Boldyrev, A. A. (2014). Antioxidant properties of semax, a drug that enhances memory and learning. Biochemistry (Moscow), 79(9), 979-984.
